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Houttuynia cordata (HC) (Saururaceae) has been used internally and externally as a traditional medicine and as an herbal tea for
healthcare in Japan. Our recent survey showed that HC poultice (HCP) prepared from smothering fresh leaves of HC had been
frequently used for the treatment of purulent skin diseases with high effectiveness. Our experimental study also demonstrated that
ethanol extract ofHCP (eHCP) has antibacterial, antibiofilm, and anti-inflammatory effects against S. aureuswhich caused purulent
skin diseases. In this study, we focused on novel effects of HCP against oral infectious diseases, such as periodontal disease and
dental caries. We determined the antimicrobial and antibiofilm effects of water solution of HCP ethanol extract (wHCP) against
important oral pathogens and investigated its cytotoxicity and anti-inflammatory effects on human oral epithelial cells. wHCP
had moderate antimicrobial effects against some oral microorganisms and profound antibiofilm effects against Fusobacterium
nucleatum, Streptococcus mutans, and Candida albicans. In addition, wHCP had no cytotoxic effects and could inhibit interleukin-
8 and CCL20 productions by Porphyromonas gingivalis lipopolysaccharide-stimulated human oral keratinocytes. Our findings
suggested that wHCP may be clinically useful for preventing oral infectious diseases as a mouthwash for oral care.
1. Introduction
It has been considered that biofilms provide an ideal envi-
ronment formicrobial colonization and growth, because they
limit the diffusion of antimicrobial agents and antiseptics
and protect pathogens against the host immune attack [1, 2].
Therefore, dental biofilm forming in the oral cavity plays crit-
ical roles in the pathogenesis of oral infectious diseases such
as dental caries and periodontal disease [3]. Moreover, oral
microorganisms have been recently recognized as pathogens
that can cause systemic chronic or severe infectious diseases
[4, 5]. In particular, our previous report showed that a higher
prevalence of Candida spp. as well as Pseudomonas aerugi-
nosa and Staphylococcus spp. was observed in patients with
cerebrovascular infarction and dysphagia [6]. Predominant
fungi in humans such as Candida albicans can cause a variety
of infectious diseases ranging from denture stomatitis to life-
threatening invasive infections such as aspiration pneumonia,
especially in immunocompromised or elderly patients [6–11].
Therefore, the reduction in adherence and biofilm formation
by oral microorganisms contributes to preventing not only
chronic oral infections but also potentially severe, systemic
opportunistic infectious diseases, especially in elderly people.
Oral keratinocytes play an important role as the first
physical barrier to bacterial invasion and organize the local
innate immune system against colonizing microorganisms.
In addition, they secrete proinflammatory mediators, such
as chemokines and cytokines, in response to various stimuli
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includingmicrobial infection and chemical irritation [12–14].
Lipopolysaccharide (LPS) from Gram-negative bacteria such
as Porphyromonas gingivalis, which is a primary periodontal
pathogen, upregulates the production of various proinflam-
matory mediators, such as interleukin- (IL-) 8 and CCL20,
via signal cascades in the gingival epithelium [13, 15–20].
Houttuynia cordataThunberg (HC) is a flowering peren-
nial herb of the Saururaceae family and is commonly used
as a health-promoting herbal tea in Japan. Our recent survey
showed that HC poultice (HCP) prepared from smothering
fresh leaves of HC in hot ashes or over charcoal fire wrapped
with big leaves such as Japanese butterbur or aluminum
foil had been frequently used for the treatment of purulent
skin diseases with high effectiveness [21]. Our experimental
study also demonstrated the anti-infective properties of HCP
ethanol extract (eHCP), such as the antibacterial, bacterio-
static, and antibiofilm effects against S. aureus including
methicillin-resistant S. aureus (MRSA) [21] which caused
purulent skin diseases including furuncles [22, 23].Moreover,
we elucidated that eHCP has the anti-inflammatory effect
to inhibit IL-8 and CCL20 productions from S. aureus
lipoteichoic acid (LTA; TLR-2 ligand) stimulated human
keratinocytes without any cytotoxic effect [21]. These find-
ings suggested that HCP might be therapeutically useful as
both antibiotic and anti-inflammatory modulators for skin
infection and inflammation, such as purulent skin diseases
including furuncle, with high and long-term effectiveness due
to various infection-fighting properties of HCP.
However, there are no reports on the biological effects
of HCP against oral infectious diseases. Hence, we focused
on the novel effects of HCP against oral infectious diseases
elicited by oral microorganisms. In this study, we first
determined antimicrobial and antibiofilm effects of a water
solution of HCP ethanol extract (wHCP), which might be
used safely compared to eHCP. Next, we investigated these
effects of wHCP against oralmicroorganisms including Strep-
tococcus mutans, a primary dental caries-causing bacterium,
and Fusobacterium nucleatum and P. gingivalis, primary peri-
odontal pathogens, and C. albicans, a primary oral mycosis-
causing fungus. We further examined cytotoxicity and anti-
inflammatory effects of wHCP on human oral keratinocytes
stimulated with P. gingivalis LPS as well as S. aureus LTA.
2. Materials and Methods
2.1. Plant Materials and Sample Preparation. HC used in this
study was collected in Kochi City and identified by Dr. K.
Fujikawa of the Kochi Prefectural Makino Botanical Garden,
and voucher specimens (FOS-007536 and FOS-007537) were
deposited there.
2.2. Preparations of Water Solution of H. cordata Poultice
Ethanol Extract (wHCP). wHCP was prepared as follows:
approximately 20 g of fresh leaves of HC wrapped in alu-
minum foil was heated at 450 W for 5min using an IH
cooker to obtain HCP. This was shaken with 5mL of ethanol
for 10min and then centrifuged for 20min at 1,500 g. After
centrifugation, the clear top layer was recovered to obtain
Table 1: Bacterial strains.
Strain Source
MRSA T31 Clinical isolate
MRSA COL Type strain
Streptococcus mutansMT8148 Clinical isolate
Streptococcus mutans UA159 Clinical isolate
Streptococcus sobrinus 1310 Clinical isolate
Streptococcus gordonii ATCC10558 Type strain
Streptococcus oralis ATCC10557 Type strain
Streptococcus constellatus 4528 Clinical isolate
Streptococcus intermedius 40138 Clinical isolate
Aggregatibacter actinomycetemcomitans Y4 Wild type
Fusobacterium nucleatum JCM8532 Wild type
Porphyromonas gingivalis ATCC33277 Type strain
Pseudomonas aeruginosa PAO1 Wild type
Escherichia coli K1 Wild type
Candida albicans CAD1 Clinical isolate
eHCP and was stored at −20∘C until wHCP preparation.
After 100𝜇L of eHCP was concentrated by drying under
reduced pressure for 1 h (WKN-PV-1200, WAKENYAKU,
Kyoto, Japan), the dried material was weighed and then
dissolved in 100 𝜇L of sterile purified water to finally obtain
wHCP.
2.3. Bacterial Strains and Growth Conditions. The bacterial
strains used in this study are shown in Table 1. Escherichia
coli and Pseudomonas aeruginosa were grown in Muller-
Hinton broth (MHB, Becton Dickinson, Sparks, MD, USA)
supplemented with 50𝜇gmL−1 of CaCl
2
and 25 𝜇gmL−1 of
MgCl
2
, and methicillin-resistant S. aureus (MRSA) strains
were grown inMHB supplementedwith 25 𝜇gmL−1 ofCaCl
2
,
12.5 𝜇gmL−1 of MgCl
2
, and 2% NaCl [24]. Streptococcus
spp. were grown in brain-heart infusion (BHI, Becton Dick-
inson) anaerobically. C. albicans was grown in Sabouraud
dextrose medium composed of 10 g L−1 of peptone and
40 g L−1 of glucose aerobically. F. nucleatum and P. gingivalis
were grown in BHI supplemented with 5𝜇gmL−1 of hemin
and 0.5 𝜇gmL−1 of menadione anaerobically. Aggregatibacter
actinomycetemcomitans was grown in Todd Hewitt Broth
(OXOID Ltd., Hampshire, UK) anaerobically. For the biofilm
formation assays of F. nucleatum, S. mutans, and MRSA T31,
Trypticase soy broth (TSB, Becton Dickinson) supplemented
with 5 𝜇gmL−1 of hemin and 0.5 𝜇gmL−1 of menadione, TSB
supplemented with 0.3% sucrose, and TSB supplemented
with 0.3% glucose were used, respectively. For biofilm forma-
tion assay of C. albicans, yeast nitrogen base medium at pH
7 containing 2.5mmol L−1 of N-acetylglucosamine (YNBNP)
[25] was used.
2.4. Susceptibility Assay. The minimum inhibitory concen-
tration (MIC) of wHCP was determined using a microbial
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broth dilution method. Approximately 106 colony forming
units (CFU) mL−1 of bacterial culture was inoculated into
100 𝜇L of medium containing a twofold serial dilution of
wHCP in a 96-well culture plate (TPP, Trasadingen, Switzer-
land) and incubated anaerobically for Streptococcus spp., A.
actinomycetemcomitans, F. nucleatum, and P. gingivalis or
aerobically for MRSA strains, P. aeruginosa, E. coli, and C.
albicans, for 20 h or 48 h at 37∘C.TheMIC was defined as the
lowest concentration showing no bacterial growth.
2.5. Biofilm Formation Assay. A crystal violet biofilm for-
mation assay was performed to quantify the biofilm mass
as described previously [26]. 2𝜇L of MRSA T31, S. mutans
MT8148, or C. albicans CAD1 at stationary phase or 5 𝜇L
of F. nucleatum JCM8532 at stationary phase suspended in
150 𝜇Lof broth ormediumas described abovewas transferred
in a U-bottomed 96-well plate (Cellstar, Greiner-Bio-One,
Frickenhausen, Germany), and then wHCP (1%, 5%, or 10%)
was added. Bacterial suspensions were incubated anaerobi-
cally for F. nucleatum JCM8532 and S. mutans MT8148 or
aerobically for MRSA T31 and C. albicans CAD1 at 37∘C
for 6 or 24 h. Distilled H
2
O (1%, 5%, or 10%) was used as
a negative control. After incubation, the biofilms formed
were washed with purified water twice without disturbing the
adherent biofilm, stained with 150𝜇L of 0.1% crystal violet for
10min at room temperature, and excess stain was removed by
gentle washing with purified water twice. After drying, the
stained biofilm was extracted from the well by adding 150 𝜇L
of ethanol, and the absorbance of the extract from stained
biofilm was measured at 595 nm using a microplate reader
(model 680; Bio-Rad Laboratories, Hercules, CA, USA).
2.6. Cell Culture. RT-7 cells, an immortalized human oral
keratinocyte cell line, kindly provided by Dr. N. Kamata
(Hiroshima University, Hiroshima, Japan) as described pre-
viously [27], were cultured in Keratinocyte-SFM (Gibco BRL,
Gaithersburg, MD, USA) supplemented with 100UmL−1 of
penicillin and 100 𝜇gmL−1 of streptomycin (Gibco BRL) at
37∘C in a water-saturated atmosphere of 95% air and 5%
CO
2
. Confluent monolayers were cultured with 1 𝜇gmL−1 of
purified S. aureus LTA (InvivoGen, San Diego, CA, USA) or
P. gingivalis LPS (InvivoGen) and/or 0.1%, 0.5%, or 1%wHCP.
2.7. Lactate Dehydrogenase (LDH) Cytotoxicity Assay. The
effect of wHCP on cell cytotoxicity was determined using
a lactate dehydrogenase (LDH) assay. Confluent RT-7 cell
monolayers in a 24-well plate were cultured in Keratinocyte-
SFM medium supplemented with 0.1%, 0.5%, 1%, or 10%
wHCP for 24 h at 37∘C. As a positive control, RT-7 cells
were treated with 0.1% Triton X-100 for 10min at room
temperature. For the cytotoxicity assay, the levels of LDH
released into the recovered cell culture supernatants were
determined using an LDH cytotoxicity assay kit (Cayman
Chemical, Ann Arbor, MI, USA) in accordance with the
manufacturer’s instructions. Absorbance was measured at
490 nm using a microplate reader (Bio-Rad Laboratories).
Table 2: MIC of wHCP.
Bacterial strain MIC
(%)∗ (𝜇gmL−1)
MRSA T31 0.3 68
MRSA COL 1.25 271
Streptococcus mutansMT8148 5 1085
Streptococcus mutans UA159 >10 >2170
Streptococcus sobrinus 1310 >10 >2170
Streptococcus gordonii ATCC10558 >10 >2170
Streptococcus oralis ATCC10557 1.25 271
Streptococcus constellatus 4528 >10 >2170
Streptococcus intermedius 40138 >10 >2170
Aggregatibacter actinomycetemcomitans Y4 >10 >2170
Fusobacterium nucleatum JCM8532 2.5 543
Porphyromonas gingivalis ATCC33277 1.25 271
Pseudomonas aeruginosa PAO1 >10 >2170
Escherichia coli K1 >10 >2170
Candida albicans CAD1 >10 >2170
∗The concentration of wHCP in medium (V/V).
2.8. Enzyme-Linked ImmunosorbentAssay (ELISA). Enzyme-
linked immunosorbent assay (ELISA) kits were used to quan-
tify IL-8 and CCL20/macrophage inflammatory protein-
3𝛼 (R&D Systems, Minneapolis, MN, USA) in cell culture
supernatants.
2.9. Statistical Analysis. All statistical analyses were per-
formed using the unpaired Student’s 𝑡-test. Differences were
considered significant when the probability value was less
than 5% (𝑃 < 0.05).
3. Results
Recently, we demonstrated that eHCP showed antibacterial
effects against MRSA [21]. However, considering the use of
HCP for oral care, ethanol in eHCP should be substituted
for other solvents, since it was cautioned in a previous
review article that ethanol in mouthwashes has potentially an
increased risk of oral cancer [28]. Therefore, we substituted
ethanol with water in eHCP and first confirmed the antimi-
crobial effects of wHCP against various microorganisms
including MRSA and oral pathogens. As shown in Table 2,
wHCP had moderate antimicrobial effects on MRSA T31,
MRSA COL, S. mutans MT8148, S. oralis ATCC10557, F.
nucleatum JCM8532, and P. gingivalisATCC33277 (MIC; 0.3–
5.0%, 68–1085 𝜇gmL−1).
We then examined the antibiofilm effects of wHCP for F.
nucleatum, S. mutans, andC. albicans, which form biofilms in
human oral cavity including denture surface [29, 30], as well
as MRSA. For this experiment, we used the culture of MRSA
T31 clinical isolate because MRSA COL had less biofilm
formation activity (data not shown). A biofilm formation
assay revealed that wHCP significantly inhibited 24 h biofilm
formation by MRSA T31 and 24 h biofilm formation by







































































Figure 1: Antibiofilm effects of water solution of Houttuynia cordata poultice ethanol extract (wHCP) on 24 h biofilm formations by MRSA
T31 (a). Antibiofilm effects ofwater solution ofHouttuynia cordatapoultice ethanol extract (wHCP) on 24h biofilm formations byF. nucleatum
(b). Distilled H
2




































































Figure 2: Antibiofilm effects of water solution ofHouttuynia cordata poultice ethanol extract (wHCP) on 6 h biofilm formation by S. mutans
MT8148 (a). Antibiofilm effects of water solution of Houttuynia cordata poultice ethanol extract (wHCP) on 24 h biofilm formations by
Candida albicans CAD1 (b). Distilled H
2
O (1%, 5%, or 10%) was used as a negative control. ∗Significant differences between the indicated
groups at 𝑃 < 0.001 using Student’s 𝑡-test.
F. nucleatum in a concentration-dependent manner (Figures
1(a) and 1(b)). The biofilm formation assay also revealed that
wHCP significantly inhibited 6 h biofilm formation by S.
mutans in a concentration-dependent manner (Figure 2(a)).
Moreover, the biofilm formation assay with C. albicans
revealed that wHCP (1%, 5%, and 10%) reduced 24 h biofilm
formation (Figure 2(b)). In each experiment, 10% wHCP
could not affect the growth of thesemicroorganisms (data not
shown). These findings revealed that wHCP had antibiofilm
activity against major oral pathogens as well as MRSA.
To confirm the absence of any cytotoxic effect of wHCP
onkeratinocytes, wemeasured the level of LDHreleased from
RT-7 cells. As a positive control, keratinocytes were treated
with 0.1% Triton X-100 for 10min. As shown in Figure 3, no
cytotoxic effect of wHCP (up to 10%) was observed. These
results indicated that wHCP may be clinically used for oral
applications.
In this study, we examined the inhibitory effects of wHCP
on IL-8 and CCL20 productions in S. aureus LTA-stimulated
or P. gingivalis LPS-stimulated RT-7 cells. At first, we con-
firmed that 1% wHCP significantly inhibited IL-8 and CCL20
productions in RT-7 cells stimulated with S. aureus LTA
(Figure 4). We also found that wHCP significantly inhibited
IL-8 and CCL20 productions in RT-7 cells stimulated with P.
gingivalis LPS for 24 h in a concentration-dependent manner
(Figure 5). However, it is unrealistic to apply wHCP in the
mouth for long period. We next examined whether short-
term pretreatment with wHCP could inhibit IL-8 and CCL20
productions in P. gingivalis LPS-stimulated RT-7 cells. IL-8
and CCL20 production in P. gingivalis LPS-stimulated RT-7






















Figure 3:No cytotoxic effect ofwater solution ofHouttuynia cordata
poultice ethanol extract (wHCP) on oral keratinocytes. As a positive
control, RT-7 cells were treated with 0.1% Triton X-100 and shaken
gently for 10min at room temperature. ∗Significant differences
versus control group at 𝑃 < 0.001 using Student’s t-test.
cells was significantly inhibited by 0.5 and 3 h pretreatments
with 1% and 0.1%wHCP, respectively (Figure 6).These results
suggested that wHCP may be clinically useful for preventing
oral infectious diseases such as periodontal disease asmouth-
wash for oral care.
4. Discussion
In this study, wHCP was shown to have antimicrobial effects
against various oral microorganisms, antibiofilm effects
against MRSA, S. mutans, F. nucleatum, and C. albicans,
and inhibitory effects on IL-8 and CCL20 productions by S.
aureus LTA-stimulated or P. gingivalis LPS-stimulated human
oral keratinocytes with no cytotoxic effect. These findings
contributed to assessing the potential for wHCP as new oral
care products.
It has been reported that HC contains various essential
oils (terpenoids, hydrocarbons, esters, alcohols, ketones,
aldehydes, acids, phenols, ethers, andmixed compounds) and
flavonoids (quercitrin, isoquercitrin, afzelin, hyperin, and
rutin) [31]. Among compounds contained in the essential
oil, aldehydes such as lauryl aldehyde and decanoyl acetalde-
hyde (houttuynin) have antimicrobial effects against Gram-
positive bacteria and antifungal effects [32–35]. Among these,
decanoyl acetaldehyde has better antimicrobial activity than
other aldehydes but shows lower stability [32]. Our present
results demonstrated that wHCP contains higher levels of
active constituents such as aldehydes because of our unique
preparation methods by the combination of smothering and
ethanol extraction.
Recent studies have reported that extracts from many
plants have antimicrobial and/or antibiofilm effects against
oral microorganisms including S. mutans, S. sobrinus, P.
gingivalis, and C. albicans [36–39]. It has been also reported
that HC has many activities such as diuretic, antibacterial,
antiviral, anticancer, and antiallergic effects [31, 40]; however,
there have not been any studies on its antimicrobial and/or
antibiofilm effects against oral microorganisms and anti-
inflammatory effects on oral keratinocytes. This study suc-
cessfully demonstrated that wHCP has antimicrobial effects
against various pathogens that normally colonize the oral
cavity (Table 2) and antibiofilm effects against major oral
pathogens, F. nucleatum, S. mutans, and C. albicans (Figures
1 and 2).
Our previous study demonstrated that CCL20 produced
by inflamed gingival epithelial cells appears to be closely
related to proinflammatory responses of the gingiva and
plays an important regulatory role in specific lymphocyte
migration into periodontal diseased tissue [18]. In addi-
tion, TLR2, a pattern recognition receptor for LTA from S.
aureus or LPS from P. gingivalis, is prominently expressed
in the pocket epithelium of periodontal tissues with chronic
periodontitis and participated in the signaling cascade to
upregulate the production of IL-8 [13, 15–17, 19, 20]. We
demonstrated that wHCP significantly inhibited IL-8 and
CCL20 productions from P. gingivalis LPS-stimulated oral
keratinocytes in a concentration-dependent manner (Fig-
ure 5). Moreover, short-term pretreatment with wHCP sig-
nificantly inhibited IL-8 and CCL20 productions in RT-
7 cells stimulated with P. gingivalis LPS (Figure 6). Taken
together, we inferred that wHCP has multiple activities
on both oral microorganisms and host cells and may be
clinically useful for the prevention of oral infectious dis-
eases, including dental caries and periodontal diseases, as a
mouthwash for oral care without cytotoxic effects. Essential
oils fromHC have anti-inflammatory effects mediated by the
inhibition of cyclooxygenase-2 by a mechanism similar to
that of nonsteroidal anti-inflammatory drugs [41] and also
by inhibiting nitric oxide and tumor necrosis factor-𝛼 pro-
duction in LPS-stimulated mouse peritoneal macrophages
[42]. Among the flavonoid glycosides from HC, quercitrin
(3-rhamnosylquercetin) had an inhibitory effect on acute
inflammatory edema induced by various phlogistic agents,
such as histamine and serotonin [43]. HC also inhibited
LTA-induced inflammation in human dermal fibroblast [44].
These previous reports and our present results suggest that
wHCP contained effective constituents involved in the host
inflammatory response to infection.
Biofilm formed by Candida spp. can provide an attach-
ment site for other microorganisms, but wHCP can inhibit
biofilm formation by C. albicans; therefore, we suggest that
wHCP might aid in preventing aspiration pneumonia. F.
nucleatum and P. gingivalis, which are oral opportunistic
bacteria, recently have been ascended to central players based
on their participation in complex codependent mechanisms
of systemic chronic diseases including cancer, rheumatoid-
arthritis, and diabetes in terms of risk and pathogenesis [5].
According to our findings showing wHCP has moderate
antimicrobial and antibiofilm effects on both F. bacterium
and P. gingivalis, we infer that wHCP might reduce risk of
progression to chronic systemic diseases from oral infection.
For oral application, smell and taste are very important
factors, in contrast to external application for skin diseases.
Because wHCP is bland and innocuous, it would be accept-
able in this respect. Considering that oral care contributes












































Figure 4: Inhibitory effect of water solution of Houttuynia cordata poultice ethanol extract (wHCP) on IL-8 (a) and CCL20 (b) productions
in oral keratinocytes stimulated with S. aureus LTA for 24 h. Significant differences versus control group at ∗
𝑃
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Figure 5: The inhibitory effects of water solution of Houttuynia cordata poultice ethanol extract (wHCP) on IL-8 (a) and CCL20 (b)
productions in oral keratinocytes stimulatedwithP. gingivalis for 24 h. Significant differences versus control group at ∗
𝑃




to systemic health, we infer that clinical applications of
wHCP may be effective for preventing oral infections, such
as dental caries, periodontal diseases, and aspiration pneu-
monia in immunocompromised hosts and elderly people.
Further studies are needed to characterize the constituents
of wHCP, which exhibit antimicrobial, antibiofilm, and anti-
inflammatory activities, and to clarify the regulatory mech-
anisms against oral microorganisms such as S. mutans, F.
nucleatum, P. gingivalis, and C. albicans.
5. Conclusions
This study demonstrated the anti-infective properties of
wHCP, including antimicrobial effects against some oral
pathogens and antibiofilm effects against F. nucleatum, S.
mutans, and C. albicans. Moreover, we elucidated that wHCP
had no cytotoxic effects and inhibitory effects on IL-8 and
CCL20 production by P. gingivalis LPS-stimulated human
oral keratinocytes. wHCP, which is bland and innocuous,
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Figure 6:The inhibitory effects of water solution ofHouttuynia cordata poultice ethanol extract (wHCP) pretreatment on IL-8 (a) and CCL20
(b) productions in oral keratinocytes stimulated with P. gingivalis for 24 h. Significant differences versus no pretreatment control group at
∗
𝑃
< 0.05 and ∗∗
𝑃
< 0.01 using Student’s 𝑡-test.
may be clinically useful for preventing oral infectious dis-
eases, including dental caries, periodontal diseases, aspiration
pneumonia, denture stomatitis, and oral candidiasis, as a
mouthwash for oral care.
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